The guidance, if finalized, would be the first to cover AI devices from design and development to post-market monitoring and risk management, according to a Jan. 6 news release from the agency.
The guidance highlights key areas, including strategies to address transparency, bias and performance monitoring.
The FDA has authorized more than 1,000 AI-enabled medical devices and the new guidance builds on previous efforts.
